From: Second generation tyrosine kinase inhibitors for the treatment of metastatic non-small-cell lung cancer
N
OR%
mPFS (mo)
mOS (mo)
Afatinib
LUX LUNG I trial 40
390
7
3.3
10.8
Placebo
195
<1
1.1
12.0
LUX LUNG IV trial 42
61
8.2
4.4
19
XL647
Phase II trial52
41
3
3.6
16.1